Yes, that's right.
COVAX is becoming yet another competitor in the global marketplace—a dysfunctional marketplace. Only the wealthiest nations are getting vaccine doses. Low-income countries have received just 0.2% of the 2.5 billion doses distributed thus far. COVAX is unable to meet its objectives. That is a real problem.
Ngozi Okonjo-Iweala, the WTO's director-general, recommended a third approach: urging vaccine makers to enter into more licensing agreements with various partners. That's obvious. If, from the outset, companies had had an interest in pursuing as many licensing agreements as possible around the world, global vaccine manufacturing capacity could have truly been leveraged. Very quickly, however, aside from AstraZeneca—